DFIB Cardiac Science (MM)

Cardiac Science to Present at CIBC World Markets 2004 Healthcare Conference IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automated public access defibrillators, announced today that Chairman and Chief Executive Officer Raymond W. Cohen is scheduled to make an investor presentation at the CIBC World Markets 2004 Healthcare Conference. The presentation will be held at 8:00 a.m. (Eastern) on Tuesday, November 9, 2004. The conference runs from November 8-10, 2004 at the Plaza Hotel in New York, NY. A live webcast of the Company's presentation at the Conference will be available via a link provided at the Company's website at http://www.cardiacscience.com/. An archive of the presentation will begin shortly after the presentation time and will be available for 30 days. About the CIBC World Markets 2004 Healthcare Conference This annual event features informative presentations and panels in the pharmaceutical, biotechnology, medical device and healthcare services industries. Attendees will have the opportunity to increase their knowledge of today's most dynamic healthcare companies and will gain a deeper understanding of the opportunities and challenges facing healthcare companies today. For more information about the conference visit: http://www.cibcwm.com/conferences/health04/. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth and the lowering of the company's breakeven revenue level by the third quarter. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. For further information please contact: Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Roderick de Greef, EVP and CFO of Cardiac Science, Inc., +1-949-797-3800, DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Roderick de Greef, EVP and CFO of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright